Cangene Corporation  

(Public, TSE:CNJ)   Watch this stock  
Find more results for CNJ
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 2.05 - 3.61
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.14
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Oct '13) 2013
Net profit margin -21.18% 1.07%
Operating margin -16.58% 8.89%
EBITD margin - 11.11%
Return on average assets -7.32% 0.52%
Return on average equity -10.76% 0.69%
Employees 700 -
CDP Score - -


155 Innovation Drive
+1-204-2754200 (Phone)
+1-204-2697003 (Fax)

Website links


Cangene Corporation (Cangene) is a biopharmaceutical company in the business of developing, manufacturing, and commercializing products and technologies for global markets. It operates in two segments: biopharmaceutical operations and contract services. The biopharmaceutical operations segment consist of sales of approved products and non- specialty plasma. The contract-services segment consists of third-party contract-manufacturing revenues at the Company�s Winnipeg facilities, as well as at Cangene bioPharma in Baltimore. It also provides commercial contract-manufacturing services, primarily through a United States-based subsidiary. The Company�s products include Rho(D) Immune Globulin (Human) for Injection (WinRho) SDF, Hepatitis B Immune Globulin (Human) Injection (HepaGam B) and Varicella Zoster Immune Globulin (Human) (VariZIG). In February 2014, Emergent BioSolutions Inc completed the acquisition of Cangene.